Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Iveena LLC (AKA: iVeena Delivery Systems inc)
Profile last edited on: 7/14/2024      CAGE: 7KKG3      UEI: EQ3KNDP93M27

Business Identifier: Intraocular drug delivery platform to treat major eye diseases
Year Founded
2010
First Award
2015
Latest Award
2023
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

525 East 100 South Suite 275
Salt Lake City, UT 84102
   (801) 213-2550
   infor@iveenamed.com
   iveenamed.com
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

iVeena, LLC. spin-out of Moran Eye Institute, is developing novel drug delivery solutions for treatment of common eye diseases that lead to blindness. iVeena will move its solutions into the market via a number of strategic channel partnerships each focused on specific drug-device combinations.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
2
Conversion Rate
40.00%
Phase I Dollars
$1,782,499
Phase II Dollars
$2,939,382
Total Awarded
$4,721,881

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $1,680,476
Project Title: Topical Eyedrop Therapy for Keratoconus
2020 2 NIH $2,246,644
Project Title: Targeted Intraceptor Nanoparticle for Macular Degeneration
2017 1 NSF $224,994
Project Title: Dual suppression of VEGF-A and PDGF-B with extended gene therapy for neovascular AMD
2017 1 NIH $224,767
Project Title: Topical Eyedrop Therapy for Keratoconus
0 1 NIH $345,000
Project Title: Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

Key People / Management

  Gerald T Simmons -- Ceo and Member of the Board of Directors

  Balamurali K Ambati -- President and Director

  Randon Michael Burr

  Sarah Abdulla Molokhia -- Research Consultant

  Rajkumar Patil -- Vice President Advanced Ocular Delivery Systems

Company News

There are no news available.